-
-
-
-
-
-
-
JPMorgan Starts Arcus Biosciences (RCUS) at Overweight
-
-
-
-
-
-
-
Arcus and Summit team up to test kidney cancer drug combo
-
-
-
-
-
-
-
Mizuho on Arcus Biosciences (RCUS): stock's dip today 'doesn't make sense'
-
-
-
-
-
-
-
Morgan Stanley Downgrades Arcus Biosciences (RCUS) to Equalweight
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) PT Raised to $28 at H.C. Wainwright
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) PT Raised to $45 at Mizuho
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) PT Lowered to $18 at H.C. Wainwright
-
483,169 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


